Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,142.3
3.5 (0.11%)

 

  • STI Straits Times Index
    3,142.3
    3.5 (0.11%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.0
    -0.6 (-0.04%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,086.4
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,381.2
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,775.8
    -194.5 (-0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,097.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 145.9M
  • Value: 155.1M
  • Rise: 122
  • Fall: 51
  • Unch: 588

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.110+0.001
MM2 Asia0.071+0.004
Metal Component0.059+0.002
Olam Intl1.280-0.060
Leader Env0.080+0.002
GSS Energy0.068+0.001
KTL Global^0.119-0.003
Singtel2.250+0.020
Serial System0.146+0.010
Mercurius0.064+0.002

World Indices

World Indices
Name Last Change
Nasdaq 14,660.6 -180.1
HSI 25,086.4
HSCEI 8,879.6
Jakarta 6,097.0
Nikkei 225 27,777.4 -192.8
SSE Comp 3,381.2
Shanghai A 3,543.7
Shanghai B 256.9
KOSPI 3,241.5 +8.9

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

REATA PHARMACEUTICALS INC REATA PHARMACEUTICALS, INC. CLASS A
Updated on 26 Jul 2021 (End of trading day)
Last (USD): 126.570 Change: -2.930 High: 130.830 Remarks: -
Change (%): -2.26 Low: 125.370
Open 130.160 Yesterday's Close 129.5
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 169,183 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -6.82929 Trailing EPS (USD) e -7.33969 NAV (USD) b 10.1807
PE a - Trailing PE f - Price / NAV b 12.4323
Dividend (USD) d - Cash In Hand (USD) g 21.4352 Issued & Paid-up Shares c 31,368,300
Dividend Yield (%) d - Price / Cash In Hand g 5.905 Treasury Shares h -
Market Cap (M) 4,591.687 Enterprise Value (M) 4,220.227
Piotroski F Score 2 Exchange Code RETA Par Value ( $ ) n.a.
52 Weeks Volatility (%) 86.60 Free Float (%) 93.6
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 10 May 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 23 May 2016.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference REATA PHARMACEUTICALS INC NASDAQ 4,591.687 - - 12.4323 -
Industry Pharmaceuticals: Major NASDAQ 2,394.326 85.972 90.486 3.3660 1.409
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 175,948.482 54.628 43.938 12.1932 2.044
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,188.659 9.274 9.274 1.6889 2.596
Local Peer ROYALTY PHARMA PLC NASDAQ 24,102.346 24.719 24.776 4.9368 0.483
Local Peer VIATRIS INC NASDAQ 16,727.854 - - 0.7811 -
Local Peer REPLIGEN CORP NASDAQ 11,310.876 188.747 142.166 7.2682 -
Local Peer CUREVAC NV NASDAQ 10,093.124 - - - -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 6,788.487 - - 15.8502 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 6,353.684 - - 30.7741 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 6,056.058 - - 6.4184 -
Local Peer APELLIS PHARMACEUTICALS INC NASDAQ 5,373.966 - - 104.0362 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 4,843.256 70.988 70.988 5.6288 -
Local Peer ALLAKOS INC NASDAQ 4,370.752 - - 7.0948 -
Other Local Peers IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), ERASCA INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), GENERATION BIO CO (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PETIQ INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), ANNEXON INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), INOZYME PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PROVENTION BIO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), ATHENEX INC (NASDAQ), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), DURECT CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GAMIDA CELL LTD (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), VINCERX PHARMA INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NEXIMMUNE INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), IMMUNIC INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), POLYPID LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), MANNATECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ)
Global Peer JOHNSON & JOHNSON NYSE 454,682.844 30.901 25.591 - 2.304
Global Peer PFIZER INC NYSE 235,662.749 24.507 21.248 3.4343 3.614
Global Peer ELI LILLY AND COMPANY NYSE 233,599.553 37.716 38.342 33.8616 1.212
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 222,311.234 27.378 24.717 4.1137 2.111
Global Peer ABBVIE INC NYSE 208,343.311 45.729 40.980 15.1965 4.101
Global Peer MERCK & CO INC NYSE 195,576.314 27.675 27.828 7.2584 3.208
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 158,236.431 24.556 23.538 17.1176 1.507
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,767.936 - - 4.0092 2.739
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 99,425.997 13.486 14.644 4.8479 5.236
Global Peer WUXI APPTEC HKEx 455,334.725 137.193 95.580 10.8775 0.228
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), SINOPHARM (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), HUTCHMED (HKEx), SH PHARMA (HKEx), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), CMS (HKEx), AKESO-B (HKEx), INNOCARE-B (HKEx), BAIYUNSHAN PH (HKEx), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), SIMCERE PHARMA (HKEx), TRAD CHI MED (HKEx), CHINAGRANDPHARM (HKEx), CSTONE PHARMA-B (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), CARSGEN-B (HKEx), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), UNITED LAB (HKEx), ANTENGENE-B (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), Kimia Farma Tbk. (IDX), TONGRENTANGCM (HKEx), IMMUNOTECH-B (HKEx), SCICLONE PHARMA (HKEx), CKLIFE SCIENCES (HKEx), ANNOVIS BIO INC (NYSE American), SHINEWAY PHARM (HKEx), ZHAOKE OPHTH-B (HKEx), HUA MEDICINE-B (HKEx), Soho Global Health Tbk. (IDX), IGBB (Bursa), RACE ONCOLOGY LTD (ASX), STARPHARMA HOLDINGS LIMITED (ASX), PYC THERAPEUTICS LIMITED (ASX), AFT PHARMACEUTICALS LTD (ASX), DAWNRAYS PHARMA (HKEx), BSTEAD (Bursa), TOT BIOPHARM-B (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PHARMA (Bursa), FUSEN PHARM (HKEx), IP (SET), LANNETT CO INC (NYSE), CH BIOTECH SER (HKEx), NOXOPHARM LTD (ASX), ZHONGZHIPHARM (HKEx), RECCE PHARMACEUTICALS LTD (ASX), IX Biopharma (SGX), Merck Tbk. (IDX), CRESO PHARMA LTD (ASX), NEW RAY MEDIC (HKEx), CHARMACY PHAR (HKEx), KOTRA (Bursa), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), Hyphens Pharma (SGX), BIOHLDG (Bursa), NOVA (Bursa), MODERN CHI MED (HKEx), EXOPHARM LTD (ASX), INVION LTD (ASX), NEP INTERLONG (HKEx), AGEX THERAPEUTICS INC (NYSE American), WAI YUEN TONG (HKEx), MEDLAB CLINICAL LIMITED (ASX), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), PURAPHARM (HKEx), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), JCT (SET), SUNZEN (Bursa), PHARMAXIS (ASX), EXTRAWELL PHAR (HKEx), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED (ASX), ACRUX (ASX), ISLAND PHARMACEUTICALS LTD (ASX), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --3.120
-2.41 %
10 Days --6.770
-5.08 %
20 Days --20.200
-13.76 %
Medium Term Return 3 Months -+23.480
+22.78 %
6 Months -+9.560
+8.17 %
1 Year --26.400
-17.26 %
Long Term Return 2 Years -+35.950
+39.67 %
3 Years -+56.460
+80.53 %
5 Years -+110.970
+711.35 %
Annualised Return Annualised --
+52.00 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 76.340 - 186.816 Change From 1 Year Low +50.230 % Change From 1 Year Low (%) +65.80
Change From 1 Year High -60.246 % Change From 1 Year High (%) -32.25
2 Years Range 70.000 - 257.965 Change From 2 Years Low +56.570 % Change From 2 Years Low (%) +80.81
Change From 2 Years High -131.395 % Change From 2 Years High (%) -50.94
5 Years Range 15.175 - 257.965 Change From 5 Years Low +111.395 % Change From 5 Years Low (%) +734.08
Change From 5 Years High -131.395 % Change From 5 Years High (%) -50.94
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Historical Price Data

Date Open High Low Close Volume VWAP
26 Jul 2021 130.160 130.830 125.370 126.570 169,183 -
23 Jul 2021 128.960 130.970 126.410 129.500 191,080 -
22 Jul 2021 131.470 132.990 128.000 128.380 122,752 -
21 Jul 2021 130.670 131.820 127.660 131.440 150,301 -
20 Jul 2021 126.850 130.840 125.830 129.690 269,732 -
19 Jul 2021 124.970 127.280 123.690 125.890 272,943 -
16 Jul 2021 130.120 133.510 126.700 127.750 181,085 -
15 Jul 2021 129.310 130.000 124.500 128.650 299,101 -
14 Jul 2021 133.580 135.210 128.845 129.550 278,352 -
13 Jul 2021 136.500 138.710 130.560 133.340 271,169 -
12 Jul 2021 140.970 142.300 137.370 137.470 354,457 -
09 Jul 2021 139.740 143.080 137.190 141.430 225,757 -
08 Jul 2021 132.130 140.930 132.130 139.360 284,100 -
07 Jul 2021 135.070 137.390 132.706 134.690 307,865 -
06 Jul 2021 139.010 141.850 134.680 135.020 387,295 -
02 Jul 2021 144.010 144.704 139.180 139.290 219,463 -
01 Jul 2021 141.530 144.460 140.580 143.020 220,882 -
30 Jun 2021 145.600 146.100 140.460 141.530 297,334 -
29 Jun 2021 152.050 153.410 145.740 146.770 294,773 -
28 Jun 2021 149.810 151.300 146.840 151.290 360,206 -
25 Jun 2021 142.190 153.180 141.460 149.950 3,557,242 -
24 Jun 2021 142.060 145.490 141.680 142.350 287,059 -
Summary
Current 2 Weeks
(13 Jul 2021 to 26 Jul 2021)
136.500 138.710 123.690 126.570 2,205,698 -
Previous 2 Weeks
(28 Jun 2021 to 12 Jul 2021)
149.810 151.300 123.690 137.470 2,952,132 -
4 Weeks from
(28 May 2021 to 25 Jun 2021)
137.650 142.170 123.690 149.950 10,317,189 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.